BOSTON - Bruker (NASDAQ:BRKR) Corporation (NASDAQ:BRKR) announced today the launch of its new 'Triceratops' SPR #64 Surface Plasmon Resonance (SPR) instrument at the SLAS2024 International Conference and Exhibition. The novel system aims to enhance drug discovery by allowing the simultaneous measurement of 64 molecular interactions, which is touted to be the highest throughput in the industry without compromising data quality.
The 'Triceratops' SPR #64 combines sensitive detection with an innovative microfluidics concept that reads 64 sensor spots at once through the rotation of an 8-channel flow cell. This design is expected to expedite various processes in drug discovery, including screening, kinetics, epitope characterization, condition scouting, concentration analysis, and thermodynamics.
The instrument includes a built-in touchscreen for immediate access and visual controls, and it features automation capabilities that can integrate external robots and direct control through an Application Programming Interface (NASDAQ:TILE) (API). The accompanying software is designed to be user-friendly and efficient for tasks such as SPR affinity and kinetics determination, thermodynamics, and epitope characterization.
Dr. David Myszka of Biosensor Tools LLC praised the new system for its flexibility, sensitivity, and throughput, noting the ease of optimizing conditions in a single run. Similarly, Dr. Martin Kleinschmidt from the Fraunhofer Institute for Cell Therapy and Immunology reported successful measurements with increased throughput using the 'Triceratops' SPR #64.
Dr. Meike Hamester, VP Label-Free Biopharma Technologies at Bruker Daltonics, highlighted the 'Triceratops' SPR #64 as a significant addition to Bruker's portfolio, which includes the SPR-24 Pro and SPR-32 Pro systems, catering to various throughput requirements.
Bruker Corporation is known for providing scientific instruments and solutions that contribute to advancements in life sciences and other fields. The company's products are used in a wide range of applications, from molecular research to diagnostics.
The information presented in this article is based on a press release statement from Bruker Corporation.
InvestingPro Insights
As Bruker Corporation (NASDAQ:BRKR) continues to innovate in the field of life sciences with the launch of its 'Triceratops' SPR #64 instrument, investors may be interested in the company's financial health and market performance. With a market capitalization of $9.99B and a P/E ratio standing at 33.4, Bruker is currently trading at a high earnings multiple. This could suggest that the market has high expectations for the company's future growth. Additionally, the company's revenue has shown impressive growth over the last twelve months as of Q3 2023, with a 12.48% increase, indicating a strong business performance.
InvestingPro Tips reveal that management's confidence is reflected through aggressive share buybacks, and analysts have taken a favorable view, with four of them revising their earnings upwards for the upcoming period. Moreover, Bruker has demonstrated a strong return over the last three months, with a 22.77% price total return, which could be a positive sign for investors looking for growth potential. It's also worth noting that the company has been profitable over the last twelve months and is expected to maintain profitability this year.
For those considering an investment in Bruker, it may be a good time to explore the additional insights available with InvestingPro. There are over 12 additional InvestingPro Tips that can provide a deeper understanding of the company's financial nuances. Plus, the InvestingPro subscription is now on a special New Year sale with a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.